Patents by Inventor Peter Neville Ingram

Peter Neville Ingram has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS
    Publication number: 20220395512
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R5b X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Application
    Filed: May 17, 2022
    Publication date: December 15, 2022
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Stephen Buxton, Matthew Habgood, Peter Neville Ingram, Chun Yan Ma, Spencer Charles Robert Napier, Abdul Kadar Shaikh, Matthew Raymond Smith, Christopher Charles Stimson, Edward Richard Walker
  • ANTIVIRAL COMPOUNDS
    Publication number: 20220356148
    Abstract: The present invention relates to novel compounds of general Formula II: wherein the groups X, and R1 to R4 have the meanings given in the description, to a process for preparing these compounds and to their use for treating, preventing or ameliorating viral infections and diseases which are associated with PLA2G16.
    Type: Application
    Filed: June 28, 2021
    Publication date: November 10, 2022
    Inventors: Wolfgang Fischl, Mark Whittaker, Christopher John Yarnold, Jean-Francois Pons, Mark Anthony Kerry, Patricia Leonie Amouzegh, Inaki Morao, Peter Neville Ingram, Ewa Iwona Chudyk
  • Compounds
    Patent number: 11364246
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R* X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: June 21, 2022
    Assignee: TMEM16A LIMITED
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Stephen Buxton, Matthew Habgood, Peter Neville Ingram, Chun Yan Ma, Spencer Charles Robert Napier, Abdul Kadar Shaikh, Matthew Raymond Smith, Christopher Charles Stimson, Edward Richard Walker
  • Antiviral compounds
    Patent number: 11091428
    Abstract: The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: August 17, 2021
    Assignee: HAPLOGEN GMBH
    Inventors: Wolfgang Fischl, Mark Whittaker, Christopher John Yarnold, Jean-Francois Pons, Mark Anthony Kerry, Patricia Leonie Amouzegh, Inaki Morao, Peter Neville Ingram, Ewa Iwona Chudyk
  • ANTIVIRAL COMPOUNDS
    Publication number: 20190225575
    Abstract: The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.
    Type: Application
    Filed: September 12, 2017
    Publication date: July 25, 2019
    Inventors: Wolfgang Fischl, Mark Whittaker, Christopher John Yarnold, Jean-Francois Pons, Mark Anthony Kerry, Patricia Leonie Amouzegh, Inaki Morao, Peter Neville Ingram, Ewa Iwona Chudyk